G
Giovanni Melillo
Researcher at AstraZeneca
Publications - 18
Citations - 5366
Giovanni Melillo is an academic researcher from AstraZeneca. The author has contributed to research in topics: Durvalumab & Head and neck squamous-cell carcinoma. The author has an hindex of 8, co-authored 18 publications receiving 3709 citations.
Papers
More filters
Journal ArticleDOI
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
Scott J. Antonia,A. Villegas,Davey B. Daniel,David Vicente,Shuji Murakami,Rina Hui,Takashi Yokoi,Alberto Chiappori,Ki Hyeong Lee,Maike de Wit,Byoung Chul Cho,M. Bourhaba,Xavier Quantin,Takaaki Tokito,Tarek Mekhail,David Planchard,Young-Chul Kim,Christos S. Karapetis,Sandrine Hiret,Gyula Ostoros,Kaoru Kubota,Jhanelle E. Gray,Luis Paz-Ares,Javier de Castro Carpeño,Catherine Wadsworth,Giovanni Melillo,Haiyi Jiang,Y. Huang,Phillip A. Dennis,Mustafa Ozguroglu,Pacific Investigators +30 more
TL;DR: Progression‐free survival was significantly longer with durvalumab than with placebo, and safety was similar between the groups, and the secondary end points also favored durvalsumab.
Journal ArticleDOI
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Scott J. Antonia,A. Villegas,Davey B. Daniel,David Vicente,Shuji Murakami,Rina Hui,Takayasu Kurata,A. Chiappori,Ki Hyeong Lee,Maike de Wit,Byoung Cheol Cho,M. Bourhaba,Xavier Quantin,Takaaki Tokito,Tarek Mekhail,David Planchard,Young-Chul Kim,Christos S. Karapetis,Sandrine Hiret,Gyula Ostoros,Kaoru Kubota,Jhanelle E. Gray,Luis Paz-Ares,Javier de Castro Carpeño,Corinne Faivre-Finn,Martin Reck,Johan Vansteenkiste,David R. Spigel,Catherine Wadsworth,Giovanni Melillo,Maria Taboada,Phillip A. Dennis,Mustafa Ozguroglu +32 more
TL;DR: Durvalumab therapy resulted in significantly longer overall survival than placebo, and no new safety signals were identified.
Journal ArticleDOI
Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.
Lillian L. Siu,Caroline Even,Ricard Mesia,Éva Remenár,Amaury Daste,Jean Pierre Delord,Jürgen Krauss,Nabil F. Saba,Lisle Nabell,Neal Ready,Irene Brana,Nuria Kotecki,Dan P. Zandberg,Jill Gilbert,Hisham Mehanna,Marcelo Bonomi,Anthony Jarkowski,Anthony Jarkowski,Giovanni Melillo,Jon Armstrong,Sophie Wildsmith,Jérôme Fayette +21 more
TL;DR: In patients with R/M HNSCC and low or no PD-L1 tumor cell expression, all 3 regimens exhibited a manageable toxicity profile and Durvalumab and durvalumAB + tremelimumab resulted in clinical benefit, with minimal observed difference between the two.
Journal ArticleDOI
Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy
Dan P. Zandberg,Alain Algazi,Antonio Jimeno,J. Good,Jérôme Fayette,Nathaniel Bouganim,Neal Ready,Paul Clement,Caroline Even,Raymond Woo-Jun Jang,Stuart J. Wong,Ulrich Keilholz,Jill Gilbert,Moon Fenton,Irene Brana,Stéphanie Henry,Éva Remenár,Zsuzsanna Papai,Lillian L. Siu,Anthony Jarkowski,Jon Armstrong,Kobby Asubonteng,Jean Fan,Giovanni Melillo,Ricard Mesia +24 more
TL;DR: Durvalumab demonstrated antitumour activity with acceptable safety in PD-L1-high patients with R/M HNSCC, supporting its ongoing evaluation in phase III trials in first- and second-line settings.
Journal ArticleDOI
A phase 3, randomized, open-label study of first-line durvalumab (MEDI4736) ± tremelimumab versus standard of care (SoC; EXTREME regimen) in recurrent/metastatic (R/M) SCCHN: KESTREL.
Tanguy Y. Seiwert,Jared Weiss,Shrujal S. Baxi,Myung-Ju Ahn,Jérôme Fayette,Maura L. Gillison,Jean-Pascal Machiels,Shunji Takahashi,Giovanni Melillo,A. Franks,Ugochi Emeribe,David Raben,Michael McDevitt,Amanda Psyrri +13 more
TL;DR: The Phase 3 KESTREL study compares D ± T with SoC EXTREME regimen for first-line treatment of R/M SCCHN and concludes that D+T combination regimens demonstrated clinical activity and manageable tolerability profiles.